ALBUQUERQUE, N.M., March 6 /PRNewswire/ -- Exagen Diagnostics, Inc., which
develops and commercializes genomic marker-based in vitro diagnostic (IVD)
kits for prognosis and prediction of treatment response, today announced that
Dr. Thomas Williams has been named chief science officer and vice president,
research and development. Williams will spearhead the company's scientific
strategy, including genomic marker validation, product development functions
and collaborative relationships with key customers.
"Exagen has benefited from Tom's expertise since the company's inception,"
said Exagen CEO James McClintic. "His extensive record of accomplishment in
clinical molecular diagnostics, molecular genetics research and clinical
research makes him the ideal person to direct our scientific efforts as we
bring our products to market."
Prior to joining Exagen as a full-time employee, Williams served as the
company's special advisor for molecular pathology. Additionally, he was vice
chairman, department of pathology, at the University of New Mexico (UNM)
School of Medicine and director of the Genetics and Cytometry Division at
TriCore Reference Laboratories, a regional medical laboratory affiliated with
UNM Health Sciences Center and Presbyterian Healthcare Services. Williams will
continue with UNM as part-time professor of pathology.
About Exagen Diagnostics, Inc.
An emerging leader in the development of prognostic and predictive in
vitro diagnostic (IVD) kits, Exagen is uniquely able to discover, validate and
productize small sets of genomic markers for use in oncology, infectious
disease and other indications. The company's first tests predict the risk of
breast cancer recurrence, so that women with a low or elevated risk of
recurrence can be identified with high accuracy. Exagen plans to submit its
tests to the Food and Drug Administration for clearance later this year, and
will be the first to market a set of genomic markers for breast cancer
prognosis using a fluorescent in situ hybridization (FISH) test. For more
information, visit http://www.exagen.com.
SOURCE Exagen Diagnostics, Inc.